Uromigos Live 2024: Focus on Bladder Cancer
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings. During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed. In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored. In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed. In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered. In this third segment, the panelists discuss bladder-sparing approaches. The second part of this four-part segment includes conversation about ctDNA in bladder cancer. The first part of four segments from the panel session on peri-operative therapy in bladder cancer. Listen to the podcast format of the peri-operative therapy in bladder cancer panel from Uromigos Live 2024. Listen to the podcast format of the panel on on emerging ADC data in bladder cancer from Uromigos Live 2024. View the live recording of the "Will New Antibody Drug Conjugates Cure Bladder Cancer?" session from Uromigos Live 2024. Featuring Tom Powles, MD; Petros Grivas, MD; Shilpa Gupta, MD; Kala Sridhar, MD; and Andrea Apolo, MD.